Guangdong Hybribio Biotech Co Ltd (300639) - Total Assets
Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) holds total assets worth CN¥4.28 Billion CNY (≈ $626.65 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Guangdong Hybribio Biotech Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Guangdong Hybribio Biotech Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Guangdong Hybribio Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data.
Guangdong Hybribio Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangdong Hybribio Biotech Co Ltd's total assets of CN¥4.28 Billion consist of 48.1% current assets and 51.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.4% |
| Accounts Receivable | CN¥1.11 Billion | 24.0% |
| Inventory | CN¥65.66 Million | 1.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥283.12 Million | 6.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Guangdong Hybribio Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Guangdong Hybribio Biotech Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong Hybribio Biotech Co Ltd's current assets represent 48.1% of total assets in 2024, a decrease from 61.8% in 2012.
- Cash Position: Cash and equivalents constituted 15.4% of total assets in 2024, up from 14.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 22.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 24.0% of total assets.
Guangdong Hybribio Biotech Co Ltd Competitors by Total Assets
Key competitors of Guangdong Hybribio Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Guangdong Hybribio Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.06 | 6.55 | 6.48 |
| Quick Ratio | 4.86 | 6.32 | 6.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.59 Billion | CN¥2.11 Billion | CN¥1.66 Billion |
Guangdong Hybribio Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangdong Hybribio Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -19.3% |
| Total Assets | CN¥4.62 Billion |
| Market Capitalization | $573.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong Hybribio Biotech Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guangdong Hybribio Biotech Co Ltd's assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guangdong Hybribio Biotech Co Ltd (2012–2024)
The table below shows the annual total assets of Guangdong Hybribio Biotech Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.62 Billion ≈ $676.49 Million |
-19.26% |
| 2023-12-31 | CN¥5.73 Billion ≈ $837.86 Million |
-14.94% |
| 2022-12-31 | CN¥6.73 Billion ≈ $984.98 Million |
+59.08% |
| 2021-12-31 | CN¥4.23 Billion ≈ $619.18 Million |
+48.11% |
| 2020-12-31 | CN¥2.86 Billion ≈ $418.06 Million |
+120.28% |
| 2019-12-31 | CN¥1.30 Billion ≈ $189.79 Million |
+9.15% |
| 2018-12-31 | CN¥1.19 Billion ≈ $173.88 Million |
+11.09% |
| 2017-12-31 | CN¥1.07 Billion ≈ $156.52 Million |
+84.69% |
| 2016-12-31 | CN¥579.15 Million ≈ $84.75 Million |
+17.28% |
| 2015-12-31 | CN¥493.83 Million ≈ $72.26 Million |
+28.05% |
| 2014-12-31 | CN¥385.66 Million ≈ $56.43 Million |
+42.30% |
| 2013-12-31 | CN¥271.02 Million ≈ $39.66 Million |
+60.13% |
| 2012-12-31 | CN¥169.25 Million ≈ $24.77 Million |
-- |
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more